UNSPSC 51386301: Meseclazone

This classification denotes a nonsteroidal antiinflammatory drug with the molecular formula C11H10ClNO3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 51KFT71THG, chemically known as 7-chloro-3,3a-dihydro-2-methyl-2h,9h-isoxazolo(3,2-b)(1,3)benzoxazin-9-one but generally known as meseclazone, which bears US NIH Compound Identifier 34445. European Medicines Agency schedules Meseclazone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08783MIG.

UNSPSC 51386301 Meseclazone is a Commodity code, but the recent state and local contract opportunities posted under it bear no meaningful relationship to meseclazone itself. The three opportunities on record—Seminole County's procurement of naloxone and drug deactivation systems, Texas HHS's RFI on direct-to-manufacturer prescription programs, and MMCAP's RFP for generic multi-source pharmaceuticals and OTC products—are all pharmaceutical procurement activities, yet none involves meseclazone as a named product or therapeutic target. The code appears to be a misapplication or a vestigial tag from a broader pharmaceutical catalog system that state and local buyers are not actively using for meseclazone-specific solicitations. State and local procurement under this code is effectively dormant or so broadly mislabeled that the code fails to predict actual purchasing intent.

The issuing bodies span a county health department (Seminole County, Florida), a state health and human services commission (Texas HHS), and a multistate cooperative purchasing alliance (MMCAP, administered by Minnesota). Activity appears concentrated in the South and Upper Midwest, with the most recent opportunity dated January 20, 2026. If meseclazone procurement activity exists in state and local markets, it is not being tagged under this UNSPSC code in publicly posted solicitations, suggesting either that the code is unused in practice or that buyers are applying different classification schemes for meseclazone products.